01 82ASTRAZENECA AB
01 66515117
02 66515117*PED
03 67919598
04 67919598*PED
05 27951400
06 28221786
07 28221786*PED
08 48361972
09 28361972*PED
10 88501698
11 68501698*PED
12 98628799
13 68716251
14 68716251*PED
15 39339472
16 49616028
17 49616028*PED
01 12Y
02 70Blank
01 40Y
02 42Blank
01 122025-07-13
02 62025-10-04
03 62026-04-04
04 82027-06-20
05 62027-12-20
06 122028-03-21
07 102028-09-21
08 22028-11-30
09 62029-12-16
10 62030-06-16
11 42030-11-12
12 42031-05-12
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2025-10-04
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 6515117
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2025-10-04
Patent Expiration Date : 2028-03-21
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8361972
Drug Substance Claim :
Drug Product Claim :
Application Number : 209091
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2028-03-21
Patent Expiration Date : 2025-10-04
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 6515117
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2025-10-04
Patent Expiration Date : 2025-10-04
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 6515117
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2025-10-04
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2025-10-04
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 6515117
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2025-10-04
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-1976
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-1977
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-06-20
LOOKING FOR A SUPPLIER?
